Estrella Immunopharma (ESLA) Stock Analysis

What Estrella Immunopharma does

Estrella Immunopharma, Inc. is an early-stage biopharmaceutical enterprise focused on creating T-cell therapies for various blood cancers and solid tumors, with its primary activities centered in the United States. The company's lead investigational drugs include EB103, which is in preclinical development for diffuse large B-cell lymphoma, and EB104, intended for the treatment of both diffuse large B-cell lymphoma and acute lymphocytic leukemia. Estrella also maintains a collaborative agreement with Imugene Limited, working together to develop solid tumor therapies that integrate Imugene's CF33-CD19t product candidate with Estrella's EB103. The company is based in Emeryville, California.

Key metrics

ETFs linked to ESLA

Broad-market and Healthcare sector ETFs an investor holding Estrella Immunopharma is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how ESLA fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Estrella Immunopharma?

Estrella Immunopharma trades under the ticker ESLA on NASDAQ.

Which exchange is ESLA listed on?

ESLA is listed on NASDAQ.

What sector does Estrella Immunopharma operate in?

Estrella Immunopharma is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze ESLA in a portfolio?

PortView shows ESLA's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.